Meeting
2018 ASCO Annual Meeting
A phase 1 multicenter study evaluating the safety and efficacy of MHC class II-restricted MAGE-A3/A6 T-cell receptor engineered T cells (KITE-718) in patients with advanced cancers.
Authors
Partow Kebriaei
The University of Texas MD Anderson Cancer Center, Houston, TX
Partow Kebriaei , Christopher Austin Klebanoff , Ben C. Creelan , David S. Hong , George R. Blumenschein Jr., Alexandra Drakaki , Ashutosh Tewari , Lisa Thomrongsith , Yizhou Jiang , Rajul K. Jain
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research
Sub Track
Cellular Immunotherapy
Clinical Trial Registration Number
NCT03139370
Citation
J Clin Oncol 36, 2018 (suppl; abstr TPS3104)
DOI
10.1200/JCO.2018.36.15_suppl.TPS3104
Abstract #
TPS3104
Poster Bd #
316b
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Phase IIA study of high-affinity TCR-T (TAEST16001) targeting NY-ESO-1 in soft tissue sarcoma.
First Author: Jiayong Liu
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Phase I study of autologous transgenic T cells expressing high affinity mesothelin-specific T-cell receptor (TCR; FH-TCR TMSLN) in patients with metastatic pancreatic ductal adenocarcinoma (mPDA).
First Author: E. Gabriela Chiorean
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A phase I study of GPC3 targeted CAR-T cell therapy in advanced GPC3-expressing hepatocellular carcinoma (HCC).
First Author: Changqing Xie
Poster
2022 ASCO Annual Meeting
Efficacy and safety of autologous expanded tumor infiltrating lymphocytes (TILs) in multiple solid tumors.
First Author: Rodabe Navroze Amaria